DOI: https://doi.org/10.22141/2224-1507.9.1.2019.163057

Efficiency and safety of ibandronic acid: focus on the results of randomized researches and meta-analysеs

N.V. Grygorievа

Abstract


This review provides current data about the efficacy, safety and tolerability of oral and parenteral forms of ibandronic acid, as well as its use in the complex treatment of systemic osteoporosis and its complications according to the results of randomized clinical trials and meta-analysеs. In addition, the results of comparative studies on the efficacy of ibandronic ­acid and other bisphosphonates are presented, its advantages and perspectives are analyzed.

Keywords


іbandronic acid; іbandronate; Bonvivа; osteoporosis; review

References


Black DM, Rosen CJ. Clinical Practice. Postmenopausal Osteoporosis. N Engl J Med. 2016 Jan 21;374(3):254-62. doi: 10.1056/NEJMcp1513724.

Povoroznjuk VV, Grigor'eva NV, Orlik TV, Nishkumaj OI, Dzerovich NI, Balackaja NI. Osteoporoz v praktike vracha–internista [Osteoporosis in the practice of an internist doctor]. Kyiv: Ekspres; 2014. 198 р . (in Russian).

Russell RG. Bisphosphonates: the first 40 years. Bone. 2011 Jul;49(1):2-19. doi: 10.1016/j.bone.2011.04.022.

Russell RG, Xia Z, Dunford JE, et al. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci. 2007 Nov;1117:209-57. doi: 10.1196/annals.1402.089.

Povoroznyuk VV. Bisphosphonates: the role of ibandronic acid in the treatment of postmenopausal osteoporosis. Zdorov`ja Ukrai'ny. 2007;(5):57-58. (in Russian).

Golovach IYu. Evolution of bisphosphonates: climbing to the summit. Mystectvo likuvannja 2009;(9-10):68-74. (in Ukrainian).

Bauss F, Russell RG. Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. Osteoporos Int. 2004 Jun;15(6):423-33. doi: 10.1007/s00198-004-1612-7.

Chesnut CH 3rd, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004 Aug;19(8):1241-9. doi: 10.1359/JBMR.040325.

Felsenberg D, Miller P, Armbrecht G, Wilson K, Schimmer RC, Papapoulos SE. Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis. Bone. 2005 Nov;37(5):651-4. doi: 10.1016/j.bone.2005.05.004.

Ettinger MP, Felsenberg D, Harris ST, et al. Safety and tolerability of oral daily and intermittent ibandronate are not influenced by age. J Rheumatol. 2005 Oct;32(10):1968-74.

Cooper C, Emkey R, McDonald RH, et al. Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab. 2003 Oct;88(10):4609-15. doi: 10.1210/jc.2003-022029.

Miller PD, McClung MR, Macovei L, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1–year results from the MOBILE study. J Bone Miner Res. 2005 Aug;20(8):1315-22. doi: 10.1359/JBMR.050313.

Reginster JY, Adami S, Lakatos P, et al. Efficacy and tolerability of once–monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis. 2006 May;65(5):654-61. doi: 10.1136/ard.2005.044958.

Miller PD, Recker RR, Reginster JY, et al. Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long–term extension study. Osteoporos Int. 2012 Jun;23(6):1747-56. doi: 10.1007/s00198-011-1773-0.

Delmas PD, Adami S, Strugala C, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one–year results from the dosing intravenous administration study. Arthritis Rheum. 2006 Jun;54(6):1838-46. doi: 10.1002/art.21918.

Bianchi G, Czerwinski E, Kenwright A, Burdeska A, Recker RR, Felsenberg D. Long–term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5–year data from the DIVA study long–term extension. Osteoporos Int. 2012 Jun;23(6):1769-78. doi: 10.1007/s00198-011-1793-9.

Recker R, Stakkestad JA, Chesnut CH 3rd, et al. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone. 2004 May;34(5):890-9. doi: 10.1016/j.bone.2004.01.008.

Adami S, Felsenberg D, Christiansen C, et al. Efficacy and safety of ibandronate given by intravenous injection once every 3 months. Bone. 2004 May;34(5):881-9. DOI: 10.1016/j.bone.2004.01.007.

Nakamura T, Ito M, Hashimoto J, et al. Clinical efficacy and safety of monthly oral ibandronate 100 mg versus monthly intravenous ibandronate 1 mg in Japanese patients with primary osteoporosis. Osteoporos Int. 2015 Nov;26(11):2685-93. doi: 10.1007/s00198-015-3175-1.

Hagino H, Ito M, Hashimoto J, et al. Monthly oral ibandronate 100 mg is as effective as monthly intravenous ibandronate 1 mg in patients with various pathologies in the MOVEST study. J Bone Miner Metab. 2018 May;36(3):336-343. doi: 10.1007/s00774-017-0839-2.

Orwoll ES, Binkley NC, Lewiecki EM, Gruntmanis U, Fries MA, Dasic G. Efficacy and safety of monthly ibandronate in men with low bone density. Bone. 2010 Apr;46(4):970-6. doi: 10.1016/j.bone.2009.12.034.

Cheng LI, Durden E, Limone B, et al. Persistance and Compliance with Osteroporosis Therapies Among Women in a Commercially Insured Population in the United States. J Manag Care Spec Pharm. 2015 Sep;21(9):824-33, 833a. doi: 10.18553/jmcp.2015.21.9.824.

Landfeldt E, Ström O, Robbins S, Borgström F. Adherence to treatment of primary osteoporosis and its association to fractures––the Swedish Adherence Register Analysis (SARA).Osteoporos Int. 2012 Feb;23(2):433-43. doi: 10.1007/s00198-011-1549-6.

Hadji P, Claus V, Ziller V, Intorcia M, Kostev K, Steinle T. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int. 2012 Jan;23(1):223-31. doi: 10.1007/s00198-011-1535-z.

Emkey R, Koltun W, Beusterien K, Seidman L, Kivitz A, Devas V, Masanauskaite D. Patient preference for once–monthly ibandronate versus once–weekly alendronate in a randomized, open–label, cross–over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin. 2005 Dec;21(12):1895-903. doi: 10.1185/030079905X74862.

Hadji P, Minne H, Pfeifer M, et al. Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II). Joint Bone Spine. 2008 May;75(3):303-10. doi: 10.1016/j.jbspin.2007.07.011.

Cooper A, Drake J, Brankin E; PERSIST Investigators. Treatment persistence with once–monthly ibandronate and patient support vs. once–weekly alendronate: results from the PERSIST study. Int J Clin Pract. 2006 Aug;60(8):896-905. DOI: 10.1111/j.1742-1241.2006.01059.x.

Derman R, Kohles JD, Babbitt A. Gastrointestinal tolerability with ibandronate after previous weekly bisphosphonate treatment. Clin Interv Aging. 2009;4:357-65.

Frampton JE, Perry CM. Ibandronate: a review of its use in the management of postmenopausal osteoporosis. Drugs. 2008;68(18):2683-707. doi: 10.2165/0003495-200868180-00011.

Lewiecki EM, Babbitt AM, Piziak VK, Ozturk ZE, Bone HG. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12–month, open–label, prospective evaluation. Clin Ther. 2008 Apr;30(4):605-21.

Harris ST, Blumentals WA, Miller PD. Ibandronate and the risk of non–vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta–analysis of phase III studies. Curr Med Res Opin. 2008 Jan;24(1):237-45. doi: 10.1185/030079908X253717.

Cranney A, Wells GA, Yetisir E, et al. Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data.Osteoporos Int. 2009 Feb;20(2):291-7. doi: 10.1007/s00198-008-0653-8.

Sebba AI, Emkey RD, Kohles JD, Sambrook PN. Ibandronate dose response is associated with increases in bone mineral density and reductions in clinical fractures: results of a meta–analysis. Bone. 2009 Mar;44(3):423-7. doi: 10.1016/j.bone.2008.10.052.

Inderjeeth CA, Glendenning P, Ratnagobal S, Inderjeeth DC, Ondhia C. Long–term efficacy, safety, and patient acceptability of ibandronate in the treatment of postmenopausal osteoporosis. Int J Womens Health. 2014 Dec 17;7:7-17. doi: 10.2147/IJWH.S73944.

Hou Y, Gu K, Xu C, Ding H, Liu C, Tuoheti Y. Dose–Effectiveness Relationships Determining the Efficacy of Ibandronate for Management of Osteoporosis: A Meta–Analysis. Medicine (Baltimore). 2015 Jul;94(26):e1007. doi: 10.1097/MD.0000000000001007.

Ma Z, Li Y, Zhou M, Huang K, Hu H, Liu X, Xu X. Predictors of Ibandronate Efficacy for the Management of Osteoporosis: A Meta–Regression Analysis. PLoS One. 2016 Mar 1;11(3):e0150203. doi: 10.1371/journal.pone.0150203.

Harris ST, Reginster JY, Harley C, et al. Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study. Bone. 2009 May;44(5):758-65. doi: 10.1016/j.bone.2009.01.002.

Paggiosi MA, Peel N, McCloskey E, Walsh JS, Eastell R. Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study. Osteoporos Int. 2014 Dec;25(12):2729-41. doi: 10.1007/s00198-014-2817-z.

Naylor KE, Jacques RM, Paggiosi M, et al. Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study. Osteoporos Int. 2016 Jan;27(1):21-31. doi: 10.1007/s00198-015-3145-7.

Epstein S, Jeglitsch M, McCloskey E. Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg. Curr Med Res Opin. 2009 Dec;25(12):2951-60. doi: 10.1185/03007990903361307.

Povoroznyuk VV, Orlyk TV, Dzerovych NI. Evaluation of the efficacy and safety of Bonviva in the treatment of systemic osteoporosis in postmenopausal women. Health of Woman. 2010;(1):69-74.

Kanis JA, McCloskey EV, Johansson H, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2013 Jan;24(1):23-57. doi: 10.1007/s00198-012-2074-y.

Watts NB, Adler RA, Bilezikian JP, et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012 Jun;97(6):1802-22. doi: 10.1210/jc.2011-3045.

Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid–Induced Osteoporosis. Arthritis Care Res (Hoboken). 2017 Aug;69(8):1095-1110. doi: 10.1002/acr.23279.






 

© Publishing House Zaslavsky, 1997-2019

 

   Seo анализ сайта